x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230385
| Product Information | |
|---|---|
| CAS No. | 73069-25-7 |
| Formula | C21H22O7 |
| Molecular Weight | 386.4 |
| SMILES | C\C=C(C)/C(=O)OC1C(OC(C)=O)C2=C(OC1(C)C)C=CC3=C2OC(=O)C=C3 |
| Product Description | Praeruptorin A may exert antiinflammatory effects in vitro in LPS-stimulated RAW 264.7 macrophages through inhibition of NF-κB signal pathway activation. Praeruptorin A and praeruptorin C can significantly up-regulate UGT1A1 expression in HepG2 cells partially via the CAR-mediated pathway. (+)-Praeruptorin A exerts distinct relaxant effects on isolated rat aorta rings, which may be mainly attributed to nitric oxide synthesis catalyzed by endothelial nitric oxide synthase. dl-Praeruptorin A has a neuroprotective effect on the injury in the acute phase of transient focal cerebral ischemia in mice,with optimal doses of 5 mg/kg and the optimal therapeutic time point of the same time of reperfusion. dl-Praeruptorin A elicits a novel target in the therapeutic prevention of postischemic cardiomyocyte death, the reason might be associated with modulating the expression of some immediate-early genes including IL-6, Fas, bax, and bcl-2 in ischemia-reperfusion myocardium. Praeruptorin A upregulates expression of nestin in experimental autoimmune myocarditis of rats, it is beneficial to facilitate nestin expression in myocarditis,and suitable in treatment of early myocarditis. Praeruptorin A has anti-osteoclastogenic activity via inhibition of p38/Akt-c-Fos-NFATc1 signaling and PLCγ-independent Ca2+ oscillation. |
| Format & Storage | |
|---|---|
| Purity | > 97% |
| Shipping | Shipped on dry ice. |
| Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
